Arbutus Biopharma Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ABUS Nasdaq 2836 www.arbutusbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arbutus Biopharma Corporation

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference - Oct 1st, 2024 11:30 am
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? - Sep 25th, 2024 1:40 pm
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year? - Sep 9th, 2024 1:40 pm
Arbutus to Participate in Two Upcoming Investor Conferences - Sep 3rd, 2024 11:30 am
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? - Aug 22nd, 2024 1:40 pm
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? - Aug 6th, 2024 1:40 pm
Q2 2024 Arbutus Biopharma Corp Earnings Call - Aug 2nd, 2024 5:51 am
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates - Aug 1st, 2024 12:40 pm
Arbutus: Q2 Earnings Snapshot - Aug 1st, 2024 11:41 am
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Aug 1st, 2024 11:30 am
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update - Jul 18th, 2024 11:30 am
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last? - Jun 13th, 2024 9:12 am
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels - Jun 6th, 2024 3:15 pm
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B - Jun 6th, 2024 3:15 pm
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure - Jun 5th, 2024 6:30 am
Arbutus to Participate in Jefferies Global Healthcare Conference - May 29th, 2024 11:30 am
Arbutus to Present Imdusiran Data at EASL Congress 2024 - May 22nd, 2024 6:00 am
Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program - May 17th, 2024 4:03 pm
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program - May 17th, 2024 2:40 pm
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value - May 17th, 2024 1:00 pm